TY - JOUR
T1 - Uncertainty management in regulatory and health technology assessment decision-making on drugs
T2 - guidance of the HTAi-DIA Working Group
AU - Hogervorst, Milou Amber
AU - Vreman, Rick
AU - Heikkinen, Inkatuuli
AU - Bagchi, Indranil
AU - Gutierrez-Ibarluzea, Inaki
AU - Ryll, Bettina
AU - Eichler, Hans-Georg
AU - Petelos, Elena
AU - Tunis, Sean
AU - Sapede, Claudine
AU - Goettsch, Wim
AU - Janssens, Rosanne
AU - Huys, Isabelle
AU - Barbier, Liese
AU - DeJean, Deirdre
AU - Strammiello, Valentina
AU - Lingri, Dimitra
AU - Goodall, Melinda
AU - Papadaki, Magdalini
AU - Toussi, Massoud
AU - Voulgaraki, Despina
AU - Mitan, Ania
AU - Oortwijn, Wija
N1 - Funding Information:
This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.
Publisher Copyright:
© 2023 The Author(s).
PY - 2023/6/16
Y1 - 2023/6/16
N2 - ObjectivesUncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface. MethodsSix online discussions among WG members (Dec 2021-Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions. ResultsThe WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: "unavailable," "inaccurate," "conflicting," "not understandable," "random variation," "information," "prediction," "impact," "risk," "relevance," "context," and "judgment." These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed. ConclusionsThe systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.
AB - ObjectivesUncertainty is a fundamental component of decision making regarding access to and pricing and reimbursement of drugs. The context-specific interpretation and mitigation of uncertainty remain major challenges for decision makers. Following the 2021 HTAi Global Policy Forum, a cross-sectoral, interdisciplinary HTAi-DIA Working Group (WG) was initiated to develop guidance to support stakeholder deliberation on the systematic identification and mitigation of uncertainties in the regulatory-HTA interface. MethodsSix online discussions among WG members (Dec 2021-Sep 2022) who examined the output of a scoping review, two literature-based case studies and a survey; application of the initial guidance to a real-world case study; and two international conference panel discussions. ResultsThe WG identified key concepts, clustered into twelve building blocks that were collectively perceived to define uncertainty: "unavailable," "inaccurate," "conflicting," "not understandable," "random variation," "information," "prediction," "impact," "risk," "relevance," "context," and "judgment." These were converted into a checklist to explain and define whether any issue constitutes a decision-relevant uncertainty. A taxonomy of domains in which uncertainty may exist within the regulatory-HTA interface was developed to facilitate categorization. The real-world case study was used to demonstrate how the guidance may facilitate deliberation between stakeholders and where additional guidance development may be needed. ConclusionsThe systematic approach taken for the identification of uncertainties in this guidance has the potential to facilitate understanding of uncertainty and its management across different stakeholders involved in drug development and evaluation. This can improve consistency and transparency throughout decision processes. To further support uncertainty management, linkage to suitable mitigation strategies is necessary.
KW - drugs
KW - health technology assessment
KW - regulatory decision making
KW - stakeholder deliberation
KW - uncertainty
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=d7dz6a2i7wiom976oc9ff2iqvdhv8k5x&SrcAuth=WosAPI&KeyUT=WOS:001024970600001&DestLinkType=FullRecord&DestApp=WOS
UR - http://www.scopus.com/inward/record.url?scp=85163889095&partnerID=8YFLogxK
U2 - 10.1017/S0266462323000375
DO - 10.1017/S0266462323000375
M3 - Article
C2 - 37325997
SN - 0266-4623
VL - 39
JO - International Journal of Technology Assessment in Health Care
JF - International Journal of Technology Assessment in Health Care
IS - 1
M1 - e40
ER -